Biotech News
Related news
ELVNEnliven Therapeutics2026-06-15 20:40 EST
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
ELVNEnliven Therapeutics2026-06-12 02:39 EST
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
REPLReplimune Group2026-08-10 12:00 EST
Replimune Announces Pricing of $150 Million Underwritten Offering
SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
ZNTLZentalis2026-08-17 20:01 EST
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
IDYAIDEAYA Biosciences2026-06-10 20:05 EST
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
ZNTLZentalis2026-08-14 02:23 EST
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
LEGNLegend Biotech Corporation2026-06-18 01:21 EST
Legend Biotech Corporation Announces Pricing of Public Offering
LEGNLegend Biotech Corporation2026-06-17 20:29 EST
Legend Biotech Corporation Announces Proposed Public Offering
DNLIDenali Therapeutics2026-06-18 12:00 EST
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
BioXcel
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
Recent company news
BTAIBioXcel2026-05-28 11:00 EST
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
BTAIBioXcel2026-05-15 11:00 EST
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
BTAIBioXcel2026-04-17 11:00 EST
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
BTAIBioXcel2026-04-08 11:00 EST
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
BTAIBioXcel2026-04-01 11:00 EST
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
Stock data
- Close
- 0.80 USD
- Market cap
- 36.74M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States